Skip to main content

neo100

Generic: Perillyl Alcohol·Code: NEO100

neo100: 3 clinical trials tracked.

neo100 evidence translation

What we can confirm

3 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about neo100, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Glioblastoma Multiforme
Clinical Trials (3)

An Open Label, Phase 1b Safety, Dose-finding, Brain Tumor Delivery, and Pharmacokinetics Study of Intranasal NEO100 in Patients With Pediatric-type Select Brain Tumors

NCT06357377·Phase 1·NTHI
Not yet recruiting

Primary endpoint: Nature and severity of adverse events

Interventionalopen12 targetStarted 2026-01Completion 2026-10Neonc Technologies, Inc.

An Open-Label, Phase 2 Study of NEO100 in Participants With Residual, Progressive or Recurrent High-Grade Meningioma

NCT05023018·Phase 2·NTHI
Recruiting

Primary endpoint: Progression free survival as six months (PFS6).

Interventionalopen30 targetStarted 2022-07Completion 2027-065 sites · United StatesNeonc Technologies, Inc.

An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or Grade IV Gliomas With IDH1 Mutation

NCT02704858·Phase 1/Phase 2·NTHI
Active, not recruiting

Primary endpoint: Phase 1 Primary Outcome: Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment

Interventionalopen49 targetStarted 2017-08Completion 2026-0811 sites · United StatesNeonc Technologies, Inc.